A Phase Ia, First-in-human, Clinical Study of the Safety, Tolerability, and Pharmacokinetics of H1710 for Injection in Participants With Advanced Solid Tumors
Latest Information Update: 04 Jun 2025
At a glance
- Drugs H 1710 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Shenzhen Hepalink Pharmaceutical
Most Recent Events
- 04 Jun 2025 New trial record